LIquid BIopsies in Patients Presenting Non-small Cell Lung Cancer

Korábbi kezelés

• Inclusion at the time of immunotherapy treatment initiation (1st or 2nd line)

Laborértékek

• Patients with histologically confirmed advanced non-small-cell lung carcinoma (stage IIIB/IV) with one of the following molecular anomalies: Epidermal Growth Factor Receptor (EGFR), B-Raf proto oncogene (BRAF) or Human Epidermal Growth Factor Receptor-2 (HER2) mutations, Anaplatsic Lymphoma Kinase (ALK) or ROS porto-oncogene 1 (ROS1) translocation, Mesenchymal-epithelial transition factor (MET) amplification, RET rearrangement.

Életkor

• Age ≥ 18 years
• Age ≥ 18 years

Egyéb

• Patients treated before their liquid biopsy
  • COHORT 2 Inclusion criteria
• Inclusion at the time of diagnosis
• Realization of tumor biopsy at the institution (Centre Léon Bérard) or outside the institution with an available histopathological report
• Covered by a health insurance
• Signed consent
  • COHORT 3 Inclusion criteria
• Patients with histologically confirmed advanced non-small-cell lung carcinoma (stage IIIB/IV) whatever the mutational or PD-L1 status.
• Realization of tumor biopsy at the institution (Centre Léon Bérard) or outside the institution with an available histopathological report
• Covered by a health insurance
• Signed consent
• Initiation of immunotherpy before their liquid biopsy

• Patients with histologically confirmed advanced non-small-cell lung carcinoma (stage IIIB/IV) regardless of the mutation status
• Inclusion at the time of diagnostic
• Realization of tumor biopsy at the institution (Centre Léon Bérard) or outside the institution with an available histopathological report
• Age ≥ 18 years
• Covered by a health insurance
• Signed consent

A regiszterben nem jelölt feltételek

• COHORT 1